Clinical and Translational Research Core

临床和转化研究核心

• 批准号: 10241581
• 负责人: DEBORAH A HOGAN
• 金额: $ 28.76万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10241581
• 关键词: Archives; Area; Aspirate substance; Basic Science; Biological Assay; Biopsy; Caring; Cells; Clinical; Clinical Research; Collaborations; Collection; Communities; Complement; Consent; Cross-Sectional Studies; Cystic Fibrosis; DNA; Data; Development; Discipline; Disease; Enrollment; Feces; Funding; Gastrointestinal tract structure; Goals; Health; Health Status; Heterogeneity; Home; Immune; Informed Consent; Inpatients; Institution; Institutional Review Boards; Intestines; Investigator-Initiated Research; Laboratories; Longitudinal Studies; Lung; Measures; Metabolic; Methods; Mission; Modeling; National Institute of Diabetes and Digestive and Kidney Diseases; Office Visits; Organ; Outcome; Patient Isolators; Patients; Physicians; Pilot Projects; Population; Preparation; Process; Prospective Studies; Proteins; Protocols documentation; Pulmonary Cystic Fibrosis; Quality Control; RNA; RNA analysis; Recording of previous events; Records; Research; Research Design; Research Personnel; Research Project Grants; Research Support; Resources; Sampling; Sampling Studies; Schedule; Scientist; Serum; Site; Specimen; Surveys; System; Testing; Time; Translational Research; Urine; Visit; Whole Blood; Work; base; biobank; body system; clinical care; cystic fibrosis patients; design; dietary; gastrointestinal; gastrointestinal system; gut microbiota; human subject; implementation facilitation; improved; inflammatory marker; insight; member; method development; novel therapeutics; patient population; ranpirnase; rectal; research study; sample collection; stool sample; success; treatment effect; treatment response

The mission of the P30-supported DartCF Clinical and Translational Research Core (CTRC) is to increase translational research in studies on the effects of cystic fibrosis disease and treatments on the gastrointestinal tract and organ systems other than the lung. The CTRC supports basic science investigators and physician-scientists by facilitating access to and analysis of clinical specimens from patients with cystic fibrosis and comparator populations. The CTRC provides assistance with all aspects of research with human subjects including study design and approval, implementation, and analysis. In addition, by acting as a central clearinghouse, the CTRC works to coordinate our portfolio of clinically based studies to minimize the burden on our patient population and clinical care team and maximize scientific impact. Samples collected include stool, serum, urine, purified immune cells, bacterial and fungal clinical isolates from patient samples and accompanying patient data as allowed by IRB-approved protocols. The CTRC is able to collect patient samples as part of both longitudinal and cross-sectional studies; longitudinal studies in which samples are paired with patient health measures are particularly important for the analysis of the effects of the gastrointestinal microbiota on outcomes. The CTRC has developed a collection of banked samples for rapid hypothesis testing and this resource can be particularly useful for obtaining preliminary data for new studies. The CTRC is available to all CF researchers at Dartmouth and partner institutions. It is central to the success of our Pilot Projects and other ongoing studies directed by members of the Dartmouth CF research community. The CTRC has four specific aims which are: (1) to support the design and approval of CF clinical and translational research studies, (2) to facilitate collection of specimens and data from CF patients and control subjects, (3) to archive clinical samples for current and future research studies, and (4) to process and analyze clinical specimens efficiently. Through these aims, we seek support research that works towards improving our understanding of CF as a systems-wide disease in order to develop the best possible treatments and cures. !

P30支持的DARTCF临床和转化研究核心（CTRC）的任务是增加 关于囊性纤维化疾病和治疗对囊性纤维化影响的转化研究 除肺以外的胃肠道和器官系统。 CTRC支持基础科学 研究人员和医师科学家通过促进和分析从 患有囊性纤维化和比较群体的患者。 CTRC在各个方面提供了帮助 对人类受试者的研究，包括研究设计和批准，实施和分析。在 此外，通过充当中央交换所，CTRC致力于协调我们的基于临床的投资组合 研究以最大程度地减少对患者人群和临床护理团队的负担并最大化科学的负担 影响。收集的样品包括凳子，血清，尿液，纯化的免疫细胞，细菌和真菌临床 由IRB批准的方案允许的患者样品和随附的患者数据分离。这 CTRC能够作为纵向和横断面研究的一部分收集患者样本。纵向 将样品与患者健康措施配对的研究对于分析特别重要 胃肠道菌群对结局的影响。 CTRC开发了 用于快速假设检验的存储样本，此资源对于获得特别有用 新研究的初步数据。 CTRC可供达特茅斯的所有CF研究人员和合作伙伴使用 机构。这对于我们的飞行员项目和其他正在进行的研究的成功至关重要 达特茅斯CF研究社区的成员。 CTRC具有四个特定目标：（1）到 支持CF临床和翻译研究的设计和批准，（2）促进收集 来自CF患者和对照受试者的标本和数据，（3）到当前和 未来的研究以及（4）有效地处理和分析临床标本。通过这些目标， 我们寻求支持研究，以改善我们对CF作为系统范围的理解 疾病以开发最佳的治疗方法和治疗方法。 呢